{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:50:50Z","timestamp":1782449450122,"version":"3.54.5"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pemphigus vulgaris is a potentially life-threatening autoimmune blistering disease for which corticosteroid minimization can be difficult when prior steroid toxicity has already occurred. We report a 60-year-old woman with severe mucocutaneous pemphigus vulgaris confirmed by clinical, immunopathologic, and serologic findings, who had previously developed femoral head avascular necrosis during high-dose prednisone therapy and also had advanced chronic kidney disease, hypoalbuminemia, and anemia. Rituximab was discussed as a guideline-supported first-line option; however, after counseling regarding its expected benefits and potential adverse effects, the patient declined rituximab. Therefore, dupilumab was introduced off-label as an adjunctive corticosteroid-minimizing approach together with oral prednisone 30\u202fmg\/day and supportive care. The Pemphigus Disease Area Index was 111 during the first treatment week and decreased to 22 by week 6, when disease control was achieved with cessation of new lesions and marked healing of pre-existing erosions. Prednisone was then tapered gradually. Complete re-epithelialization was achieved by approximately month 4 while the patient was receiving oral prednisone 7.5\u202fmg\/day, and clinical stability was maintained through month 6 after dupilumab discontinuation at month 4. No adverse events were observed. This case supports the clinical feasibility of dupilumab-assisted corticosteroid minimization in selected patients with pemphigus vulgaris and major treatment-related constraints, while further evidence is needed regarding patient selection, duration of therapy, and long-term relapse risk.<\/jats:p>","DOI":"10.3389\/fmed.2026.1859006","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:33:14Z","timestamp":1782448394000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Dupilumab as a corticosteroid-sparing adjunct in severe mucocutaneous pemphigus vulgaris with prior avascular necrosis and chronic kidney disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Qingbi","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial People's Hospital East Sichuan Hospital, Dazhou First People's Hospital","place":["Dazhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Yan","sequence":"additional","affiliation":[{"name":"North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FengCong","family":"Liu","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunshui","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Suining Central Hospital","place":["Suining, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linli","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Suining Central Hospital","place":["Suining, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of Dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"825796","DOI":"10.3389\/fimmu.2022.825796","article-title":"A novel combined use of Dupilumab for treatment of aggressive refractory pemphigus vulgaris complicated with pulmonary tuberculosis: a case report and the RNA-seq analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jdcr.2022.10.035","article-title":"Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris","volume":"31","author":"Moore","year":"2023","journal-title":"JAAD Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdcr.2023.09.018","article-title":"Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus","volume":"42","author":"Jiang","year":"2023","journal-title":"JAAD Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cpdd.798","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of Dupilumab in healthy adult subjects","volume":"9","author":"Li","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.autrev.2020.102661","article-title":"The role of T cells in pemphigus vulgaris and bullous pemphigoid","volume":"19","author":"Fang","year":"2020","journal-title":"Autoimmun Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of Dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1859006\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:33:39Z","timestamp":1782448419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1859006\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":10,"alternative-id":["10.3389\/fmed.2026.1859006"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1859006","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1859006"}}